Skip to content
OpenCapital
Get started

Metagenomi Therapeutics, Inc. MGX Q3 2025 earnings

Reported November 11, 2025 · Before market open

Revenue$8.7MBeat by $836.4K
EPS-$0.55Beat by $0.05
Revenue estimate$7.8M
EPS estimate-$0.60

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$3.0M
EPS estimate-$0.55

Versus estimates

Revenue

Q1 2026$1.2MMiss by $4.7MQ4 2025$3.9MMiss by $3.4M
Q3 2025$8.7MBeat by $836.4K
Q2 2025$8.5MBeat by $573.0KQ1 2025$4.1MMiss by $4.2MQ4 2024$9.6MBeat by $382.7K

Diluted EPS

Q1 2026-$0.61Miss by $0.01Q4 2025-$0.60Miss by $0.02
Q3 2025-$0.55Beat by $0.05
Q2 2025-$0.54Beat by $0.14Q1 2025-$0.68Miss by $0.06Q4 2024-$0.63Miss by $0.01

Ask the moment Metagenomi Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Metagenomi Therapeutics, Inc. report Q3 2025 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q3 2025 earnings on November 11, 2025 before market open.
What were Metagenomi Therapeutics, Inc. 's Q3 2025 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $8.7M and eps of $-0.55 for Q3 2025.
Did Metagenomi Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $7.8M by $836.4K. EPS beat the consensus estimate of $-0.60 by $0.05.
How did Metagenomi Therapeutics, Inc. 's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 24.8% from $11.5M a year earlier and eps declined 22.2% from $-0.45.
Where can I find Metagenomi Therapeutics, Inc. 's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-276135) and the 10-Q periodic report (0001193125-25-276150) directly on SEC EDGAR. The filing index links above go to sec.gov.